Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.

Autor:	Zhang, Xiaotian1 (AUTHOR), Liang, Han1,2 (AUTHOR), Li, Ziyu1 (AUTHOR), Xue, Yingwei1,3 (AUTHOR), Wang, Yanong4 (AUTHOR), Zhou, Zhiwei5 (AUTHOR), Yu, Jiren6 (AUTHOR), Bu, Zhaode1 (AUTHOR), Chen, Lin7 (AUTHOR), Du, Yian8 (AUTHOR), Wang, Xinbao8 (AUTHOR), Wu, Aiwen1 (AUTHOR), Li, Guoli9 (AUTHOR), Su, Xiangqian1 (AUTHOR), Xiao, Gang10 (AUTHOR), Cui, Ming1 (AUTHOR), Wu, Dan7 (AUTHOR), Chen, Li11 (AUTHOR), Wu, Xiaojiang1 (AUTHOR), Zhou, Yanbing12 (AUTHOR)
Zdroj:	Lancet Oncology. Aug2021, Vol. 22 Issue 8, p1081-1092. 12p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu